OpenEvidence has reportedly raised $250 million in a new funding round that values the healthcare artificial intelligence company at $15 billion, continuing a rapid rise in investor interest around specialized medical AI. The round was reportedly led by Andreessen Horowitz, with hospital systems also participating, although OpenEvidence has not publicly disclosed the full investor list or financing details. The valuation follows a $250 million round in January 2026 that valued the company at $12 billion, up from roughly $6 billion in October 2025.
Building AI Around Physicians
Founded in 2022, OpenEvidence has developed an AI-powered medical search platform designed specifically for physicians seeking clinical research, guidelines, and other medical evidence. Rather than competing directly with general-purpose systems such as ChatGPT or Claude, the company focuses on delivering information within a specialized clinical context while linking responses to sources physicians can review. Its strategy reflects the broader growth of vertical AI, where companies build products tailored to specific industries and professional workflows.
OpenEvidence has previously said that more than 40% of U.S. physicians use its platform, which supported around 18 million clinical consultations by verified doctors during December 2025. The company has also reported usage across more than 10,000 hospitals and medical centers, giving it access to a professional audience with frequent information needs. That scale of adoption has become central to its investment story as healthcare organizations increasingly evaluate AI tools that can be incorporated into daily clinical activity.
From Medical Search to Clinical Workflows
OpenEvidence is also expanding beyond standalone medical search toward deeper integration with healthcare systems and clinical software. In September 2026, Memorial Sloan Kettering Cancer Center announced a partnership with the company to integrate OpenEvidence into Epic-based clinical workflows and incorporate the OncoKB precision oncology knowledge base into its platform. Such integrations could make the technology more closely embedded in how physicians access specialized information while working with patients.
The company has operated a model that gives physicians free access while generating revenue through advertising aimed at medical professionals and other commercial relationships. By the time of its January financing, OpenEvidence had reportedly surpassed $100 million in annualized revenue, suggesting that growing clinical adoption was beginning to translate into meaningful commercial activity. However, maintaining a clear separation between sponsored content and medical information will remain important as the platform expands.
Capital for Expansion and Computing
The latest $250 million financing gives OpenEvidence additional resources to invest in product development, computing infrastructure, and expansion across healthcare institutions. Specialized AI services can require substantial computing capacity, particularly as usage grows and companies deploy multiple models across large volumes of medical information. Additional capital could also support deeper integrations with electronic health records and the development of products designed for specific medical specialties.
The funding arrives as competition in healthcare AI increases, with larger technology companies including OpenAI and Anthropic developing services for the sector. Those companies bring substantial computing resources and advanced general-purpose models, while OpenEvidence is seeking to differentiate itself through specialization, physician adoption, clinical integrations, and relationships with medical information providers. The emerging competition highlights a wider question across AI markets over whether industry-focused applications can maintain durable advantages against larger foundation-model providers.
Valuation Expectations Rise
OpenEvidence's increase from roughly $6 billion in October 2025 to $15 billion in September 2026 reflects expectations that its physician user base can develop into a much larger healthcare technology business. At a reported annualized revenue level above $100 million earlier this year, its valuation already represented a substantial multiple of current commercial activity, placing significant weight on future growth. Investors are therefore betting not only on medical search adoption but also on the company's ability to become increasingly embedded within healthcare workflows.
Reports have also raised the possibility that OpenEvidence could eventually attract acquisition interest as large technology companies increase their healthcare ambitions and AI infrastructure costs continue rising. No confirmed acquisition offer has been disclosed, and the company could continue pursuing an independent growth strategy supported by its expanding investor base. Any strategic value would likely extend beyond its technology to include physician relationships, healthcare integrations, and access to a specialized professional market.
OpenEvidence's latest financing underscores growing investor interest in AI companies that solve narrowly defined problems within large, high-value industries. Its reported $15 billion valuation is supported by rapid physician adoption, rising revenue, medical-data partnerships, and an expanding role within clinical workflows, but it also raises expectations for continued commercial growth and defensibility. The company's next stage will depend on whether it can convert widespread physician usage into a sustainable healthcare platform while maintaining trust and competing with much larger AI providers.